Schering/Cor Therapeutics Integrilin reduces death/myocardial infarctions in PURSUIT trial.
Executive Summary
SCHERING/COR INTEGRILIN REDUCES DEATH OR MI INCIDENCE IN UNSTABLE ANGINA in the Platelet IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, M. L. Simoons, MD, Thoraxcenter (Rotterdam, the Netherlands), reported Aug. 25 at the European Society of Cardiology meeting in Stockholm. Therapy with Cor Therapeutics' Integrilin (eptifibatide) led to an absolute reduction in the incidence of death or re-infarction in unstable angina patients of 1.5% after 30 days.